Business Context and Reporting Period
This Form 8-K Current Report was filed by Accendra Health, Inc. on September 16, 2026. The filing discloses significant executive leadership changes, specifically the appointment of a new President and Chief Executive Officer (CEO) and the creation of a new Chief Commercial Officer (CCO) role. The report details the transition plan from the retiring CEO, Edward A. Pesicka, to the incoming CEO, Kenneth Gardner-Smith.
Key Financial Metrics
The filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive compensation arrangements and personnel changes.
Material Changes and Executive Compensation
The primary material change is the succession of the CEO and the restructuring of the commercial leadership team. Key compensation terms for the new CEO, Kenneth Gardner-Smith, effective early in the fourth quarter of 2026, include:
- Base Salary: $1,000,000 annually.
- Annual Cash Bonus: Target of 130% of base salary, prorated for fiscal 2026.
- Long-Term Incentives: Target grant date fair value of $6,000,000, split 25% in restricted stock units, 25% in stock-settled performance share units, and 50% in cash-settled performance share units.
- Sign-on Bonus: One-time cash payment of $650,000 payable after six months, subject to repayment if voluntarily resigned within 24 months.
- Inducement Grant: One-time cash-settled stock appreciation rights with a target value of $2,000,000, vesting over three years.
Additionally, Scott Lloyd was named Chief Commercial Officer, effective October 5, 2026, to consolidate commercial strategy, sales, and partnerships.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance or specific operational outlook metrics. Management commentary indicates the new CCO role is intended to simplify the commercial structure, instill greater discipline, and drive growth as the company scales as a pure-play home-based care provider. The transition of the CEO is expected to be smooth, with the retiring CEO serving as an advisor during the handover.
Investor Verification Checklist
- Verify the exact start date for Kenneth Gardner-Smith's role as CEO in Q4 2026.
- Review the full text of the Offer Letter (Exhibit 10.1) for specific vesting schedules and performance metrics for the equity awards.
- Confirm the terms of the Officer Severance Policy and Executive Change in Control Severance Agreement referenced in the filing.
- Monitor the press release (Exhibit 99.1) for additional details on Scott Lloyd's background and specific commercial strategy initiatives.
- Check subsequent filings for the formal resignation of Edward A. Pesicka from the Board of Directors.